Le Lézard
Classified in: Health, Covid-19 virus
Subjects: SVY, AVO

New Children's Health Defense/Zogby Strategies Poll finds 32% believe Dr. Anthony Fauci has Pharma's Best Interest at Heart


WASHINGTON, April 5, 2021 /PRNewswire/ -- In a recent nationwide Zogby online poll, when asked about their viewpoints on Dr. Anthony Fauci, 32% of respondents indicated they believed he had the "pharmaceutical industry's best interest at heart" vs. that of the public. Among three groups: 18- to 29-year-olds, Hispanics, and Blacks; the percentages regarding the viewpoint that Fauci represents Big Pharma's interests were even higher (41%, 42%, and 38%, respectively).

Within approximately three months of reporting, through March 26, 2021, there have been 50,861 injuries including 2,249 deaths following receipt of COVID-19 vaccines according to the Vaccine Adverse Events System (VAERS). (Note, reports of death to VAERS following vaccination do not necessarily mean the vaccine caused the death.) Amid ever-increasing calls from government officials that the entire U.S. population be vaccinated against COVID-19, the poll also asked participants about their viewpoints on the Congress-given legal immunity vaccine manufacturers enjoy for deaths and injuries following vaccination. The liability shield from lawsuits, unique in America's free market system that incorporates product liability law, was established by Congress with the National Childhood Vaccine Injury Act of 1986 and reinforced by Congress in February 2020 with an amendment to the PREP Act.

Poll replies indicated that one-third of respondents believe vaccine manufacturers should not have liability protection in the event someone is injured or dies as a result of vaccination vs. 39% who say they should, leaving 28% unsure. When it came to vaccination status, a majority of the sample (59%) reported not having received an Emergency Use Authorization (EUA) COVID-19 vaccine vs. 41% who have. The poll had a margin of error of +/- 3.2 percentage points. For more information on COVID-19 research and American's rights to not take an Emergency Authorized Use vaccine, visit Children's Health Defense.

Contact
Rita Shreffler
202-599-1461

SOURCE Children's Health Defense


These press releases may also interest you

at 17:05
The global autism spectrum disorder therapeutics market size is estimated to grow by USD 766.1 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 6.78% during the forecast period. Increasing prevalence of...

at 14:20
The global gastroesophageal reflux disease (GERD) market  size is estimated to grow by USD 879.8 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  3.2%  during the forecast period.  Rising geriatric...

at 12:48
Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S ("Ascendis"), a global biopharmaceutical company headquartered in Copenhagen, Denmark. Under the terms of...

at 12:36
Imperial Tobacco Canada Limited ("ITCAN") has officially submitted its feedback to Health Canada regarding the proposed Ministerial Order on nicotine replacement therapy products (NRTs). ITCAN strongly believes that NRTs, especially innovative...

at 12:20
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...

at 12:10
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...



News published on and distributed by: